AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Inmune Bio, Inc. Director's Dealing 2019

May 11, 2019

34518_dirs_2019-05-10_dd7ff8b2-3779-422a-bc9e-d09dd54f92a5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Inmune Bio, Inc. (INMB)
CIK: 0001711754
Period of Report: 2019-05-08-06:00

Reporting Person: Powers Linda F (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-05-08-06:00	Common Stock	P	61667	$9.00	Acquired	1120000	Direct

Footnotes

F1: Includes (i) 700,000 shares held by Toucan Capital Fund III, LP and (ii) 420,000 shares held by Linda F. Powers ("Powers"). Toucan Capital Fund III, LP is managed by Powers. Powers holds all voting and dispositive power over the shares of common stock held by Toucan Capital Fund III, LP